


## Argipressin

<b>Cat. No.:</b>	HY-P0049
<b>CAS No.:</b>	113-79-1
<b>Molecular Formula:</b>	C <sub>46</sub> H <sub>65</sub> N <sub>15</sub> O <sub>12</sub> S <sub>2</sub>
<b>Molecular Weight:</b>	1084.23
<b>Sequence:</b>	Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH <sub>2</sub> (Disulfide bridge: Cys1-Cys6)
<b>Sequence Shortening:</b>	CYFQNCPRG-NH <sub>2</sub> (Disulfide bridge: Cys1-Cys6)
<b>Target:</b>	Vasopressin Receptor
<b>Pathway:</b>	GPCR/G Protein
<b>Storage:</b>	Sealed storage, away from moisture and light, under nitrogen
	Powder    -80°C    2 years
	-20°C    1 year
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : ≥ 100 mg/mL (92.23 mM)  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	0.9223 mL	4.6116 mL	9.2231 mL
	5 mM	0.1845 mL	0.9223 mL	1.8446 mL
	10 mM	0.0922 mL	0.4612 mL	0.9223 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Argipressin (Arg8-vasopressin) binds to the V1, V2, V3-vascular arginine vasopressin receptor, with a K <sub>d</sub> value of 1.31 nM in A7r5 rat aortic smooth muscle cells for V1.
<b>IC<sub>50</sub> &amp; Target</b>	V2 Receptor
<b>In Vitro</b>	Argipressin binds to the vascular arginine vasopressin receptor, V1, with a K <sub>d</sub> value of 1.31 nM in A7r5 rat aortic smooth muscle cells. It also stimulates the intracellular release of calcium in A7r5 cells (EC <sub>50</sub> =5 nM) <sup>[1]</sup> . AVP-induced [Ca <sup>2+</sup> ] <sub>i</sub> signals and immunized activity against S-100 in DRG cell culture. The minimum effective concentrations of Argipressin causing [Ca <sup>2+</sup> ] <sub>i</sub> responses are 100 pM in non-neuronal cells in DRG culture <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## CUSTOMER VALIDATION

- Chemosphere. 2021 Apr;269:128776.
- Biochem Pharmacol. 2022 Sep 29;115265.
- J Cell Mol Med. 2022 Oct 14.
- Front Pharmacol. 2019 Nov 15;10:1380.
- Front Neurosci. 2022 Mar 25;16:838942.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Thibonnier M, et al. Multiple signaling pathways of V1-vascular vasopressin receptors of A7r5 cells. *Endocrinology*. 1991 Dec;129(6):2845-56.
- [2]. Moriya T, et al. Vasopressin-induced intracellular Ca<sup>2+</sup> concentration responses in non-neuronal cells of the rat dorsal root ganglion. *Brain Res*. 2012 Nov 5;1483:1-12.
- [3]. Keun Suk Park, et al. Role of vasopressin in current anesthetic practice. *Korean J Anesthesiol*. 2017 Jun; 70(3): 245–257.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA